Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer by Zloza, Andrew et al.
Workshop on challenges, insights,
and future directions for mouse
and humanized models in cancer
immunology and immunotherapy: a
report from the associated programs
of the 2016 annual meeting for the
Society for Immunotherapy of cancer
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Zloza, A., A. Karolina Palucka, L. M. Coussens, P. J. Gotwals,
M. B. Headley, E. M. Jaffee, A. W. Lund, et al. 2017. “Workshop
on challenges, insights, and future directions for mouse and
humanized models in cancer immunology and immunotherapy:
a report from the associated programs of the 2016 annual
meeting for the Society for Immunotherapy of cancer.” Journal for
Immunotherapy of Cancer 5 (1): 77. doi:10.1186/s40425-017-0278-6.
http://dx.doi.org/10.1186/s40425-017-0278-6.
Published Version doi:10.1186/s40425-017-0278-6
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491969
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
MEETING REPORT Open Access
Workshop on challenges, insights, and
future directions for mouse and humanized
models in cancer immunology and
immunotherapy: a report from the
associated programs of the 2016 annual
meeting for the Society for Immunotherapy
of cancer
Andrew Zloza1, A. Karolina Palucka2, Lisa M. Coussens3, Philip J. Gotwals4, Mark B. Headley5, Elizabeth M. Jaffee6,
Amanda W. Lund7, Arlene H. Sharpe8, Mario Sznol9, Derek A. Wainwright10, Kwok-Kin Wong11
and Marcus W. Bosenberg12*
Abstract
Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and
advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The
Society for Immunotherapy of Cancer (SITC) convened a workshop titled, “Challenges, Insights, and Future
Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy” as part of the SITC 31st
Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused
on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and
weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in
cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most
common immunocompetent and humanized models used in cancer immunology and immunotherapy research,
and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop
presentations and subsequent panel discussion.
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Introduction
Translating preclinical findings into meaningful clinical
outcomes can be a costly and inefficient process, as evi-
denced by the fact that approximately 85% of oncology
drugs to enter clinical testing fail to gain approval by the
U.S. Food and Drug Administration (FDA) [1]. There is
a pressing need to develop preclinical models that will
accurately predict efficacy and toxicity prior to in-
human clinical testing. In order to advance understand-
ing of the current status and future directions of mouse
and humanized models used in cancer immunology and
immunotherapy research, SITC held a workshop as a
part of the SITC 31st Annual Meeting and Associated
Programs on November 10, 2016. This workshop pro-
vided an overview of current models used in the field,
with a focus on accurately modeling the tumor micro-
environment (TME), as well as the use of murine models
to evaluate the efficacy and toxicities of immune-
targeting therapies. The program concluded with an
open panel discussion driven by questions from the
audience.
Meeting report
Introduction to models of immunotherapy
Major questions related to immunotherapies that require
models to address
Mario Sznol, MD (Yale School of Medicine) opened the
session with a presentation on clinical issues with
immune-based approaches that will require preclinical
models to address. In his presentation, Dr. Sznol sum-
marized the factors that contribute to development of
cancer and can later determine the response to therapy,
including host genetics, lifetime environmental expo-
sures, T cell receptor (TCR) repertoire, carcinogenesis,
and evolution of the tumor and tumor-host immune
relationship.
Inhibition of the PD-1/PD-L1 pathway has shown
broad clinical activity across a variety of malignancies.
However, only a portion of patients respond to anti-PD-
1/L1 therapies, and appropriate animal models are
needed to identify additional targets in order to increase
response rates. The need to better understand the biol-
ogy of response and the effect of the TME is evident in
the large number of trials recently initiated to test com-
bination approaches in unselected patient populations.
Dr. Sznol highlighted areas for future investigation, in-
cluding the need to identify the antigens recognized by
antitumor T cells, understand mechanisms governing T
cell infiltration into tumors, define the influence of
tumor biology on antitumor immune response, and de-
termine whether other immune cells (e.g., natural killer
[NK] cells, NK T cells, B cells, etc.), inhibitory pathways,
or antibodies are capable of eliciting an antitumor re-
sponse. Dr. Sznol concluded by presenting an ideal
scenario in which tumor types would be matched to a
specific animal model in order to investigate clinical effi-
cacy and predict the toxicity of novel therapeutic
interventions.
Overview of mouse-mouse models
Marcus Bosenberg, MD, PhD (Yale School of Medicine)
presented an overview of immunocompetent mouse-in-
mouse models used in cancer immunotherapy research,
including genetically engineered mouse models
(GEMMs), chemically induced models, and syngeneic
graft models. He highlighted the types of currently avail-
able models, their utility, the strengths and weaknesses
of each model, and ways to improve upon current sys-
tems (Table 1). In doing so, Dr. Bosenberg emphasized
that models can be used both to understand the basic
biology of the immune system and to test novel im-
munotherapies in predictive models. Both aspects will
be important to drive the field forward; however, devel-
oping reliable models to predict clinical outcome in
humans may be more difficult.
Dr. Bosenberg also highlighted work from his group
on the development of a variety of Yale University
Mouse Melanoma (YUMM) syngeneic cell lines that ex-
hibit high somatic mutational burden [2], some of which
will be available from American Type Culture Collection
(ATCC) within the next few months. One of the lines,
YUMMER1.7 (YUMM Exposed to Radiation), has been
shown to regress after a brief period of growth in a wild
type (WT) C57BL/6 background. This regression can be
overcome by injecting high numbers of YUMMER1.7
cells, although previously injected mice develop CD4 + −
and CD8 + −dependent immunity against higher doses
of tumor challenge [3]. Moreover, tumors generated from
the YUMMER1.7 line are titratable and respond to im-
mune checkpoint inhibition. Dr. Bosenberg concluded by
reviewing pathological features of the melanoma tumors
in these models, including early myeloid infiltration, T cell
infiltration at day 7, immune mediated killing at day 8,
and tumor regression versus escape by days 15–18.
Overview of humanized mice models
Karolina Palucka, MD, PhD (The Jackson Laboratory for
Genomic Medicine) began her presentation by providing
an overview of the approaches used to generate human-
ized mice, including adoptive transfer of human immune
cells, transplantation of human hematopoietic cells with
or without accessory tissues in pre-conditioned immu-
nodeficient hosts, genetic editing of immunodeficient
hosts, and genetic editing of immunocompetent mice.
Dr. Palucka summarized her group’s work on first gener-
ation Onco-Humice, in which human T cells were trans-
planted into NOD/SCID β2-microglobulin-deficient
mice. In this model, breast cancer cells grew rapidly
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despite the presence of tumor infiltrating lymphocytes
(TIL). These experiments led to a model describing the
tumor-promoting inflammation observed in breast can-
cer in which Th2 polarization contributes to the inhib-
ition of an antitumor CD8+ T cell response. Dr. Palucka
highlighted complications of this model including the
eventual development of graft-versus-host disease
(GVHD).
Dr. Palucka presented examples of progress in the field
utilizing humanized mice with host modifications, in-
cluding MISTRG mice [4], MISTRG6 [5], NSG with mu-
tant KIT [6], BAFF for antibody immunity [7], NSG-
SGM3 with CSF1-tg for macrophages and IL2-tg for NK
cells [8], NSG-FcRg knock-out for intravenous IgG ther-
apy [9], and next generation humanized mice from the
Jackson Laboratory [10]. She concluded by outlining
current challenges, including considerations for model-
ing the mouse and thymic environment as well as hu-
man T cell maturation and selection. Finally, Dr. Palucka
identified practical considerations for making autologous
humanized mice, sourcing hematopoietic progenitor
cells (e.g., bone marrow, blood, cord blood, induced
pluripotent stem cells), and finally accommodating for
variations in diverse host microbiomes.
Overview of patient-derived Xenograft models
Andrew Zloza, MD, PhD (Rutgers Cancer Institute of
New Jersey) concluded the first session with an overview
of patient-derived xenograft (PDX) models, which are
subsets of humanized mice with patient engraftments
that have been used in models of infectious disease,
transplant, GVHD models, and cancer. The PDX models
used for cancer research are created by transferring dis-
sociated single cells from patient biopsies into immuno-
deficient mice. Over time, these tumors grow into
patient-derived tumors. The advantage of the PDX
model system over cell line-derived tumor models is the
ability to model diverse tumor types directly from pa-
tients and potential retention of non-tumor cells from
the human TME [11]. Tumors can also be fragmented
instead of dissociated, and surgically transplanted into
mice, resulting in rapid tumor growth (vessels will start
to infiltrate within 48–72 h). Using this method, real-
time testing of therapeutic interventions could be used
to inform clinical decisions, although there are advan-
tages and disadvantages when using both fragmentation
and dissociation methods to generate PDX models
(Table 2).
Among the benefits of utilizing PDX models is the
ability to study metastasis [12, 13]. In addition, tumors
engrafted in the original PDX models can be expanded
and passaged into subsequent generations of mice. How-
ever, the resulting tumors lose some aspects of the ori-
ginal patient tumor characteristics with each generation
[12, 13]. PDX models have also been shown to model
patient’s disease course with respect to local and distant
metastases as well as overall patient outcomes, illustrat-
ing the prognostic value of these models [12, 14]. Of
Table 1 Mouse-in-mouse models
Model Examples Characteristics Possible Improvements
Genetically
engineered
(GEMMs)
• Transgenic
• Knock-in/out
• Long latency
• Incomplete penetrance
• Few somatic mutations
• Physiological mitotic rate and tumor microenvironment
• Low rate of metastasis
• Difficult to induce effective immune responses
• High bar for therapies being tested and potentially good
model to mimic immunologically incompetent tumors
• Increasing antigenicity
○ Mutator alleles
○ Chemical carcinogenesis
○ Model antigens
• Enhanced immune backgrounds
Chemically
induced
• 3′methylcholanthrene
(MCA)
• Fully penetrant
• Variable latency
• Unclear histological cancer type
• High number of somatic mutations
• Can be very immunogenic
• Often used as syngeneic grafts
Syngeneic • Engraftment of
mouse cancer cell
lines
○ B16, MC38, CT26,
RMA, YUMM, etc.
• Easy, inexpensive, and fast to use
• Typically subcutaneous injection of cells
• Tumor can grow very quickly
• Variable immunogenicity
• Variable response to immunotherapy
• Hard to compare across models
• Drive genes are frequently unknown
• Contribution of endogenous retrovirus is not known
• Mutation burden is frequently high
• Use multiple lines driven by human-
relevant genetic changes
• Series of similar lines with variable
mutational burden
• Ability to evaluate antigen-specific
responses
• Advanced imaging available to
follow immune responses
sequentially
• Evaluate anti-tumor response at
metastatic sites
• Make lines from inbred cells using
CRISPR
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note, there are a variety of organizations that are offering
PDX models commercially [15]. Concluding with the fu-
ture of PDX models, Dr. Zloza highlighted the potential
for creating double-humanized mice by engrafting both
the patient’s tumor and peripheral blood immune cells.
In studies using this combination approach, these
models lead to good immune reconstitution and main-
tain proportions of immune cell populations that reflect
that of the patients from which the models are derived.
Thus, this technique offers an exciting avenue to directly
model the human immune system and the TME.
Session II: Modeling the tumor microenvironment
Evaluation of the tumor microenvironment
The second session of the workshop opened with a pres-
entation by Mark B. Headley, PhD (University of Califor-
nia, San Francisco) that focused on modeling the TME.
Dr. Headley began by describing the TME as a complex
network of cells (tumor cells, immune cells, fibroblasts,
endothelium, etc.) that cross-communicate and modu-
late the antitumor immune response. Notably, the TME
differs by cancer type, patient, lesion, and can even vary
within the same lesion. Since immune cells in the TME
can support or inhibit tumor growth and survival, an
understanding of the TME composition and function of
these cells provides important diagnostic and prognostic
information. For example, tumor-associated macro-
phages (TAM) are typically pro-proliferation, pro-
angiogenic, pro-metastatic, and immunosuppressive. In
contrast, NK cells, conventional CD103+ DC, and ef-
fector CD8+ T cells, which also populate the TME, act
in an antitumor capacity to protect the host from cancer.
Neutrophils can be viewed as having both pro- and anti-
tumor functions.
Dr. Headley then presented an overview focusing on
the mechanisms that balance the pro- and antitumoral
functions of myeloid cell populations [16]. Investigations
of primary murine and human tumors revealed a com-
bination of macrophage and DC populations within the
TME that arise from distinct cell lineages [17]. These re-
sults were used to identify a high-DC gene signature that
correlated with better patient outcomes [17]. Intravital
imaging illustrated conventional DC-CD8+ T cell inter-
actions in the metastatic and primary tumor draining
lymph nodes (LN), and elimination of conventional DC
in murine models resulted in increased tumor growth,
metastasis, and reduced survival. In both primary and
metastatic tumors, conventional DC (likely CD103+) set
an equilibrium with macrophages, restricting overall
tumor growth and metastasis through activation of CD8
+ T cells [18]. Dr. Headley concluded by emphasizing
that the analysis of cell populations within the TME can
yield critical knowledge of the functions of these distinct
cell populations and provide prognostic insight into hu-
man disease.
Factors affecting tumor – Microenvironment interactions
Historically, mesothelioma is chemotherapy resistant
and recent therapeutic advancements have demonstrated
only modest improvements in OS compared with previ-
ous therapies [19]. Highlighting work from her labora-
tory on the biology of the TME in the setting of
mesothelioma, Lisa M. Coussens, PhD (Oregon Health
and Sciences University) described the complexity of the
TME, which is typically skewed to a Th2-prosurvial, pro-
inflammatory, pro-angiogenic, profibrotic, immunosup-
pressive microenvironment that can impede drug
delivery and limit response to therapy. Investigations
into the cellular composition of human mesothelioma
have shown that macrophages are the major immune
cell infiltrate present, regardless of the type of chemo-
therapy or type of mesothelioma [20]. Utilizing multiplex
immunohistochemistry, it was found that chemotherapy
induces infiltration of CD206+ macrophages that are as-
sociated with a Th2/M2 phenotype.
Dr. Coussens’ group used syngeneic mouse models of
mesothelioma to determine whether macrophages are a
valid therapeutic target in this setting. In light of the fact
that the colony-stimulating factor receptor axis (CSF1/
CSF1R) is predominantly expressed by macrophages and
is required for macrophage maturation [21], and that
CSFR1 blockade depleted 50% of macrophages in mice
with late-stage disease, the group started by inhibiting
the CSF1/CSF1R axis. As monotherapy, reductions in
macrophages did not decrease tumor burden or increase
survival in the mice. Similarly, although the combination
of chemotherapy and CSF1R blockade improved cellular
apoptosis, led to an influx of CD8+ T cells, and a 50%
reduction in primary tumor burden, these effects did not
result in increased survival. Instead, lung metastases
Table 2 Methods used to generate PDX models
Dissociation method
Advantages Disadvantages
• Unbiased representation/
sampling of whole tumor
(unlike sectioning)
• Ability to challenge a large
number of mice with primary
tumor cells (especially when
injected within a supporting/
collagen matrix)
• Dissociation capabilities and
forces may bias the number
and type of cells
• The formation of mouse-
human hybrid tumor (increases
with number of passages)
• Tumor microenvironment
(TME) is not preserved
Fragmentation method:
Advantages Disadvantages
• TME is maintained (hypoxia,
acidity, cell:cell interactions,
tissue architecture)
• May better reconstitute the
immune component to some
degree
• Not representative of the
entire tumor (spatially
segregated subclones and
immune cells)
• Cannot study early tumor
formation and responses
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were resistant to therapy and although the combination
successfully depleted macrophages that were recruited
to the lungs, there was no recruitment of CD8+ T cells
to the metastases. The addition of a PD-L1 inhibitor to
the combination controlled the lung metastases and sig-
nificantly improved survival compared with combination
therapy alone. Dr. Coussens concluded by emphasizing
that appropriate modeling is essential to the develop-
ment of rational combination approaches.
Vascular regulation of the tumor microenvironment and
immune responses
Amanda Lund, PhD (Oregon Health & Science Univer-
sity) presented work on the role of vascular regulation at
the interface of a developing malignancy and the sys-
temic immune response. The vasculature coordinates
the trafficking of leukocytes as they become activated
and re-enter the site of inflammation to mediate effector
functions. However, tumor-associated vasculature is hy-
perplastic and dysfunctional: it maintains the fluid dy-
namics of tissue, which can regulate hypoxia, impact
drug delivery, and can act as a route of metastasis. These
functions are regulated by members of the vascular
endothelial growth factor receptor (VEGFR) family that
drive the migration, proliferation, and integrity of endo-
thelial cells. Importantly, the endothelial phenotype in T
cell inflamed and non-inflamed tumors has been shown
to directly inhibit lymphocytes from infiltrating tumors
[22]. Thus, reevaluation of the anatomy or the vascula-
ture may provide insights into the barriers encountered
by T cell-mediated antitumor immunity, and inspire
novel immunotherapeutic approaches to overcome
these.
Murine models have proved useful in clarifying the
role of the vasculature during an immune response, and
lymphatic vessels in particular were found to be neces-
sary for de novo antitumor immunity in an implantable
murine melanoma model [23, 24]. Inhibition of VEGF-
C/D and absence of dermal lymphatic vessels impaired
inflammatory carcinogenesis [25], whereas VEGF-C
overexpression in the TME drove lymphangiogenesis
and regional immunosuppression [24]. Thus, while ne-
cessary for immunity, lymphatic function may also lead
to immune dysfunction and suppression when activated
in an aberrant manner. Flow cytometry was used to
examine both the blood and lymphatic endothelial cells
in order to understand this complex dependency. Using
this method, it was found that tumor associated lymph-
atic vessels respond to the changing immunologic con-
text within tumor microenvironments and express
various regulatory and adhesion molecules that may in-
fluence CD8+ T cell responses. Interactions between in-
flamed, cutaneous lymphatic vessels and egressing
lymphocytes may represent a novel point of immune
control. Targeting these barriers may, in combination
with immunotherapy, drive immune cell priming, infil-
tration, retention, and function.
Components of the tumor microenvironment that modulate
tumor immune responses
Kwok-Kin Wong, MD, PhD (Dana-Farber Cancer Insti-
tute, Harvard Medical School) presented work using
conditional mouse lung cancer models using intranasal
Cre recombinase adenovirus to modulate tumor-relevant
genes at specific times, resulting in lung cancer induc-
tion with almost complete penetrance. He explained that
low mutational load and the low-throughput nature rep-
resent limitations of this approach. In the EGFR/KRAS
model, PD-1 blockade decreases factors in the TME that
are immunosuppressive for these EGFR-driven tumors
[26]. In addition, long-term PD-1 blockade results in in-
creased progression-free survival and OS in this model.
Unlike humans, these mice develop resistance to PD-1
blockade, which provides the opportunity to investigate
changes in the TME that influence mechanisms of
resistance.
Dr. Wong presented several approaches to increase
the mutational load in next generation GEMMs, to in-
crease their utility in studying the antitumor immune re-
sponse. In the first approach, KRAS/p53-, KRAS/p53/
LKB1-, and EGFR/p53-deficient transplantable cell lines
were exposed to irradiation or a carcinogen, or were
combined with DNA damage response (DDR) gene in-
activation in vitro. These cells were then transplanted
orthotopically to study alterations in the immune re-
sponse. In another technique, an organotypic culture
was developed to test combination therapies in a high-
throughput fashion [27]. Lung nodules from GEMMs
were extracted and seeded into three-dimensional (3D)
microfluidics chambers to grow spheres containing ma-
lignant cells as well as immune cell populations [28, 29].
This technique allows for a variety of parameters to be
measured. Once established in culture, light microscopy
can be used to track growth, cytokine analyses can be
performed, and fluorescence or confocal microscopy can
be used to view cellular interactions in real-time. More-
over, this technique can be performed for murine-
derived as well as patient-derived tumor spheres. These
data indicate that organotypic tumor spheroids derived
from murine models can be used in a high-throughput
manner to study the TME and correlate with treatment
outcomes in patients.
Session III: Modeling evaluation of immune therapies
Evaluation of immune checkpoint inhibitors in mice
Arlene H. Sharpe, MD, PhD (Harvard Medical School)
presented work evaluating immune checkpoint therapies
in mouse models. Dr. Sharpe opened her presentation
Zloza et al. Journal for ImmunoTherapy of Cancer  (2017) 5:77 Page 5 of 9
with an overview of the PD-1 pathway, noting that acti-
vation of the PD-1 receptor leads to downstream signal-
ing that results in reduced TCR signaling, cytokine
production, and target cell lysis [30]. PD-L1 can be
expressed on a wide variety of hematopoietic cells, non-
hematopoietic cells, and tumor cells in the TME. The
function of PD-L1 on tumor cells is not clear; it may re-
flect an inflamed tumor environment and/or contribute
to immunosuppression [31]. To investigate the function
of PD-L1 on MC38 tumors, PD-L1 was deleted on
MC38 tumor cells and the growth of PD-L1-expressing
and PD-L1-deficient tumors was comparable. However,
deletion of PD-L1 in MC38 tumors increased suscepti-
bility to clearance. These results were further validated
in a mixed competition assay in which PD-L1-sufficient
tumor cells were transplanted alongside PD-L1-deficient
tumor cells. In these experiments, the tumor cells lack-
ing PD-L1 were selectively eliminated. Thus, PD-L1 on
tumor cells has a dominant role in limiting antitumor
immunity to MC38 tumors. However, the role of PD-L1
expression on tumors is tumor-dependent. Analogous
studies of PD-L1-deleted Brafv600 PTEN-deficient tu-
mors and B16 tumors revealed that PD-L1 expression
on host cells has dominant role in limiting immune re-
sponses to these tumors. The dominance of PD-L1 on
tumors may be influenced in part by the immunogen-
icity of the tumor.
Re-evaluating the role of IDO1 in brain cancer; humanized
Immunocompetent mice take center stage
Derek A. Wainwright, PhD (Robert H. Lurie Compre-
hensive Cancer Center at Northwestern University Fein-
berg School of Medicine) opened his presentation with
an overview of glioblastoma multiforme (GBM), noting
that these central nervous system (CNS) tumors are uni-
versally fatal and their diffuse nature, heterogeneity, and
resistance to cytotoxic monotherapy all contribute to the
challenges associated with treatment. Since T cells can
infiltrate the CNS, a phenomenon commonly seen in
primary glioblastoma [32], Dr. Wainwright’s laboratory
utilizes murine models to approximate this aspect of the
disease. The most common model for glioblastoma is
the syngeneic GL261 orthotopic mouse glioblastoma
model in which GL261 glioblastoma cells are stereotac-
tically implanted intracranially. In this model, there is a
progressive increase in Treg from one to three weeks
during tumor development [33]. However, when B16-
F10 cells were used in this model, there was no increase
in Treg, indicating that tumor-intrinsic mechanisms
drive this infiltration [34]. This finding underscores the
significance of Treg in glioblastoma and is functionally
validated by increased survival in mice with intracranial
glioblastoma and neutralized for Treg infiltrates [33].
Indoleamine 2,3 dioxygenase 1 (IDO1) is an IFN-
inducible enzyme that converts tryptophan to kynure-
nine and has been shown to suppress effector T cell
functions and activate and expand Treg [35–40]. The
depletion of tryptophan and/or accumulation of kynure-
nine leads to functional inactivation of CD8+ T cells
and/or induction of Treg [41]. In the GL261 model, a
substantial increase in survival is seen when mice are
intracranially-engrafted GL261 cells stably knocked
down for IDO1 expression. This survival advantage is
also observed when GL261 cells are injected into mice
with a systemic IDO1 deficiency. However, the survival
advantage is abrogated when implanted into T cell-
deficient mice, highlighting the dual importance of
tumor cell IDO1 inhibition, in addition to the presence
of an intact immune system for eliciting effective tumor
rejection [42]. In humans, high IDO1 mRNA levels are
prognostic for decreased GBM patient survival. Notably,
increased levels of CD3ε/CD8α mRNA correlate with
higher IDO mRNA, suggesting that the presence of T
cells regulates IDO1 expression. In the syngeneic mouse
model using GL261 cells, simultaneous treatment with
standard of care radiotherapy, as well as PD-1 and IDO-
1 blockade, synergistically increased survival, durably.
Extrapolating these findings to the clinical arena, Dr.
Wainwright proposes a combinatorial therapy consisting
of radiotherapy plus checkpoint blockade and IDO-1 in-
hibition for the treatment of adults diagnosed with in-
curable GBM.
Developing new immunotherapies in preclinical models and
humans
Elizabeth M. Jaffee, MD (The Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins University) ad-
dressed ways to accelerate the development of
immunotherapy for resistant or immunologically inert
tumors. There are several challenges in treating malig-
nancies that do not respond to current immune check-
point therapy. First, methods to induce functional
effector T cell recruitment must be developed. Each can-
cer and cancer subtype may have a unique TME, illus-
trating the need to understand immunosuppressive
mechanisms that have a clinical impact. Another charac-
teristic that can indicate a lack of response to immune
checkpoint inhibitor therapy is a paucity of effector T
cells. In contrast to melanoma, which shows spontan-
eous infiltration of CD8+ T cells, pancreatic cancers are
infiltrated with suppressive Treg and myeloid-derived
suppressor cells (MDSC). Combination approaches to
address these challenges will require novel trial designs
and clinical development pathways to gain regulatory
approval by the FDA.
Dr. Jaffee proposed a two-step process for the effective
treatment of currently immunotherapy-unresponsive
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tumors: reprogramming the TME and optimizing the
immunotherapeutic modality to generate a lasting anti-
tumor response. Efforts to reprogram the TME should
focus on improving tumor antigen presentation and ab-
rogating local immunosuppression [43]. Using work
from her group to illustrate these ideas, Dr. Jaffee de-
scribed a study using the whole tumor cell vaccine,
GVAX, in the neoadjuvant and adjuvant setting. In this
study, GVAX was given two weeks prior to surgery. Fol-
lowing surgery, the patients went on to receive adjuvant
chemotherapy. Two weeks after a single vaccine treat-
ment, biopsies from 85% of patients had peri- and intra-
tumoral lymphoid aggregates with features reminiscent
of tertiary lymphoid structures. Upregulation of PD-1
was noted in the macrophage and dendritic cell popula-
tions within the lymphoid aggregates, which led to an
ongoing trial of neoadjuvant GVAX with or without PD-
1 inhibition. The potential for personalized immune
checkpoint inhibitor therapy based on individual patient
expression of immune checkpoints was also raised.
What information provided by models will inform immune
drug development and use?
Philip Gotwals, PhD (Novartis Institutes for BioMedical
Research, Inc.) provided an industry perspective on in-
formation gained from models that help direct drug de-
velopment and optimize current therapies. Questions to
be addressed through basic and translational research in-
clude patient selection based on knowledge of resistance
and biomarkers, determining optimal therapeutics for a
given cancer type, and defining appropriate dosing, se-
quencing, and combinations of therapy. According to
Dr. Gotwals, all the models discussed in this workshop
could answer such questions; the difficulty is that there
are too few models specific to cancer immunotherapy,
and limited availability compared to the large libraries of
patient-derived xenograft (PDX) models developed to
test targeted genetic mutations.
Dr. Gotwals went on to present work from a few on-
going Novartis initiatives, including chimeric antigen re-
ceptor (CAR)-T cell approaches targeting TIM-3 and
exploiting the effects of signaling through the stimulator
of interferon genes (STING) pathway. The STING study
focused on use of syngeneic models to study the antitu-
mor immune effects of activating dendritic cells using
STING agonists. ADU-S100, a potent cyclic dinucleotide
STING agonist, has been shown to induce an abscopal
effect and establish immunological memory in a dual
flank model using B16 melanoma cells [44]. Combin-
ation approaches have also been used in this setting to
illustrate that the abscopal efficacy of ADU-S100 com-
bined with immune checkpoint inhibition is dependent
on CD8+ T cells. Currently in phase I to assess the phar-
macodynamic effects of ADU-S100 in injected as well as
distal lesions, these clinical trials are designed to inform
further testing in syngeneic models.
Session IV: Panel discussion and future directions
Future directions for the development and use of cancer
immune models
The panel discussion, moderated by Dr. Bosenberg, in-
cluded all Workshop presenters and was driven by ques-
tions from the audience. Highlights included a
discussion on the need for paired pretreatment and bi-
opsies while patients are on treatment and responding in
order to get a better understand of the mechanisms
underlying response. The preference for multiple biop-
sies in clinical trials was expressed; however, multiple bi-
opsies can raise ethical concerns in addition to
considerations of patient compliance and safety. As an
alternative to multiple tumor biopsies, patient-derived
peripheral blood mononuclear cells (PBMC) could be
used in PDX models generated from patient’s tumors.
The use of models to predict the timing and sequencing
of combination approaches was also discussed, as limita-
tions initially attributed to models may actually be the
result of improper sequencing and/or dosing of therap-
ies. Finally, the panel addressed questions regarding the
use of models to develop treatments for immunologic-
ally inert tumors in which tumor-specific T cells may be
present but non-functional. Models are necessary to de-
termine the underlying mechanisms behind this
phenomenon, which will be key to developing therapies
to treat these diseases.
Conclusions
Dr. Bosenberg offered concluding remarks and summa-
rized the main themes from the day. Syngeneic models
are cost-effective and easy to use; however, GEMM may
better approximate the TME and vascular architecture,
but tend to have low neoepitope/mutation burden. Ad-
vances in humanized mouse models are rapidly progres-
sing, and with time, will hopefully bridge the gap
between mouse-in-mouse models and clinical experi-
ence. The unique milieu of the TME can have a signifi-
cant impact on response to therapy via suppressive
mechanisms that are not yet entirely understood.
Highlighting the diversity and promise of the types of
models presented, Dr. Bosenberg emphasized that reli-
able pre-clinical models will be essential to understand-
ing mechanisms of response as well as resistance to
immunotherapy. Although each model has strengths and
weaknesses, advances in modeling the dynamic inter-
action between the immune system and cancer will be
critical to advances in the field, particularly in the devel-
opment of rational combination approaches.
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